Current approaches in glioblastoma multiforme immunotherapy

Area of Science:

• Neuro-oncology
• Immunology
• Cancer Research

Background:

• Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults.
• Current treatments, including surgery, have limited efficacy, with a median survival of less than two years.
• The invasive nature of GBM makes complete surgical resection challenging, leading to frequent relapses.

Purpose of the Study:

• To review current immunotherapy approaches for glioblastoma multiforme (GBM).
• To explore the molecular mechanisms underlying these immunotherapies.
• To discuss the clinical applications and challenges of immunotherapy in GBM treatment.

Main Methods:

• Review of existing literature on glioblastoma immunotherapy.
• Analysis of various immunotherapeutic strategies targeting innate and acquired immune responses.
• Examination of molecular mechanisms and clinical trial data.

Main Results:

• Multiple immunotherapeutic strategies are under investigation for GBM.
• Approaches include CAR T-cell therapy, immune checkpoint inhibitors, and dendritic cell vaccines.
• Reprogramming tumor-associated macrophages and antibody-based therapies are also explored.

Conclusions:

• Immunotherapy presents a promising alternative for treating glioblastoma multiforme (GBM).
• Further research is needed to optimize current immunotherapies and overcome response limitations.
• Targeting both innate and adaptive immunity may improve outcomes for GBM patients.